Several Investors have Realized the Opportunity within this Upcoming Segment (Antibody Drug Conjugat

Over the years, monetary assistance from angel investors, venture capitalists and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed start-ups / small companies to further their R&D efforts related to the ADC therapeutics. In this chapter, we have reviewed the various capital investments that have been made into the ADC therapeutics market. It includes details of only those instances wherein investments were made into different companies / research institutes for the development of ADC molecules, offering insights on how the overall market has evolved in terms of investment activity. We have also highlighted the most active venture capital investors in this domain.

During our research, we were able to identify around 90 funding instances between 2011 and 2019, amounting to a total of nearly USD 4.7 billion. As can be seen in the figure, the number of funding instances in this domain have been increasing over the last few years. In fact, in 2019, we identified 6 instances of funding till July 2019.

According to our research, more than 80% of the total investment (in terms of the amount invested) was made in last five years alone; a total amount of nearly USD 3.9 billion has been invested since 2015. Further, maximum amount was invested in 2018, amounting to a total of approximately USD 1.3 billion.

In terms of grants, the total capital amount awarded in the given time period was calculated to be over USD 65 million. Further, Tulane university (4 grants) and Scripps Research (6 grants) were awarded the maximum amount, which account for USD 3.2 million, each. Additionally, Children’s Hospital of Philadelphia was awarded approximately USD 3.1 million across 4 grants.

A detailed information on the key players, partnerships inked by the developers, funding and investment activity, number of grants awarded, number of patents filed, key opinion leaders in this domain and the likely market evolution, was done by Roots Analysis in H2 2019. For Further, information visit this link.

The ‘Antibody Drug Conjugates Market (5th Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

• A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency.
• Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.

Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.